Project Grant 1549586

The U.S. Department of Defense (DoD) Defense Health Agency awarded a $1,820,004 Project Grant to Case Western Reserve University's Office of Research Administration Division, doing business as the University Hospitals of Cleveland, under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "HEMOSEAL: COMBINATORIAL NANOPARTICLE TECHNOLOGY FOR POINT-OF-INJURY HEMORRHAGE CONTROL," will support the development of an innovative nanoparticle-based technology...

The Texas A&M Engineering Experiment Station (Tees) was awarded a $2,404,778 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will support research and development of expandable hemostats for treatment of noncompressible intracaivitary hemorrhage from August 15, 2022 to August 14, 2026. Through this funding, Tees will investigate medical solutions for uncontrolled bleeding on the battlefield,...

The U.S. Department of Defense's Defense Health Agency has awarded a $902,109 Project Grant to North Carolina State University (NC State) under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "HEMOSEAL: COMBINATORIAL NANOPARTICLE TECHNOLOGY FOR POINT-OF-INJURY HEMORRHAGE CONTROL," supports the development of advanced nanoparticle-based technologies to improve hemorrhage control at the point of injury. The award period runs from July 1, 2024 to...

Federal Grant Award Summary The National Science Foundation (NSF) awarded $305,000 through its Technology, Innovation, and Partnerships program (CFDA 47.084) to Limax Biosciences Inc. for a Phase I Small Business Innovation Research (SBIR) project commencing October 1, 2025 and concluding September 30, 2026. The award supports the development and optimization of HemoMax, a bioinspired hemostatic hydrogel adhesive designed to address uncontrolled bleeding in surgical settings. The hydrogel...

Karios Technologies LLC, a for-profit organization, received a $274,954 SBIR Phase I grant from the National Science Foundation (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a novel, ready-to-use, large volume delivery system for in situ forming biomaterials. The biomaterials are intended to serve as tissue sealants, scar tissue reducers, and vehicles for drug or cell delivery during surgical procedures. The project aims to transfer a proprietary biomaterial...

This $999,783 Phase II Small Business Innovation Research (SBIR) cooperative agreement from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports Intact Therapeutics' development of a thermogel-based drug delivery platform for the treatment of upper gastrointestinal bleeding (UGIB). Intact Therapeutics' proprietary thermogel technology aims to rapidly stop UGIB prior to endoscopic treatment, potentially reducing patient morbidity,...

Case Western Reserve University will receive $2,469,361 from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program to support the SANGUISTOP project. This four-year Project Grant will fund research into intravenous nanomedicine for targeted thrombin delivery in hemorrhage control. The Military Medical Research and Development program aims to transform military and public health care through innovative medical solutions for...

This $100,000 Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program will support the development of an advanced wound care technology at Florida International University. Specifically, the university will create a bandage-integrated platform that provides feedback-mediated wound therapy to enable personalized care. The conformable platform is designed to non-invasively monitor multiple wound biomarkers in spatial detail and then apply targeted...

The Department of the Army Medical Command awarded Cayuga Biotech Inc. a $922,870 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will support Cayuga Biotech's development of an intravenous agent for traumatic hemorrhage control from July 1, 2021 to June 30, 2022. The Military Medical Research and Development program aims to transform military and public health through innovative medical research solutions, including investigations into...

Federal Project Grant Award Summary Limax Biosciences Inc. received a $464,229 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate HEMOMAX, a biodegradable hydrogel adhesive sealant for vascular surgery. The award, obligated on August 20, 2025, with completion targeted for July 31, 2026, supports a Phase I effort to advance the product toward FDA approval and commercial viability. The...